Comparative Pharmacology
Head-to-head clinical analysis: EDARBYCLOR versus TRIVARIS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EDARBYCLOR versus TRIVARIS.
EDARBYCLOR vs TRIVARIS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
EDARBYCLOR is a fixed-dose combination of azilsartan medoxomil, an angiotensin II receptor blocker (ARB), and chlorthalidone, a thiazide-like diuretic. Azilsartan selectively blocks AT1 receptors, reducing angiotensin II-mediated vasoconstriction, aldosterone secretion, and renal sodium reabsorption. Chlorthalidone inhibits sodium-chloride cotransport in the distal convoluted tubule, increasing excretion of sodium, chloride, and water, thereby reducing plasma volume.
TRIVARIS combines an opioid agonist-antagonist (buprenorphine) and a mu-opioid receptor antagonist (naloxone). Buprenorphine partially binds to mu-opioid receptors, reducing withdrawal and craving, while naloxone precipitates withdrawal if injected, deterring abuse.
One tablet (azilsartan medoxomil 40 mg / chlorthalidone 12.5 mg or 40 mg / 25 mg) orally once daily.
TRIVARIS 10 mg orally once daily, with or without food.
None Documented
None Documented
Terminal elimination half-life is approximately 11-12 hours for azilsartan medoxomil; clinical consequence: supports once-daily dosing for 24-hour blood pressure control
Terminal half-life 12-18 hours; allows twice-daily dosing in chronic therapy
Renal (approximately 60% as unchanged drug and metabolites), biliary/fecal (approximately 40%)
Renal: 60% unchanged; Biliary/Fecal: 30% as metabolites; 10% minor pathways
Category C
Category C
Angiotensin II Receptor Blocker/Thiazide Diuretic Combination
Angiotensin II Receptor Blocker + Calcium Channel Blocker + Thiazide Diuretic Combination